Lika® is Created Expressly for Those Who Crave Meat-like Taste and Texture – and Want to Eat Healthier While Contributing Towards the Well-being of Our Planet

SAN DIEGO, CA / ACCESSWIRE / February 28, 2018 / The Amazing Protein Company (www.amazingprotein.com) continues its Whole Foods Market Southern California roll-out by bringing its acclaimed Lika® vegan cuisine to the Whole Foods market Hillcrest location in San Diego this weekend from Friday, March 2-Sunday March 4. The company will be handing out samples of two of its Lika® popular entrees – BBQ beef and Chinese-style Beef & Broccoli.

The Whole Foods Market Hillcrest store is located at 711 University in San Diego.

Lika® represents the next generation of meat alternatives for the burgeoning vegan market. The Lika® differences can be found in the way its dishes can be custom-seasoned – in contrast to all other vegan prepared food products that must be pre-seasoned due to their inability to absorb flavoring during the cooking process. As a result, the revolutionary Lika™ food preparation technology represents a game-changer within the hotly-competitive vegan prepared food arena, empowering customers to enjoy a wide array of delicious vegan alternatives their way.

In developing its flagship Lika® line of products, the Amazing Protein Company, Inc. has achieved a milestone scientific breakthrough in the food technology of plant protein. While other plant proteins-based product requires pre-seasoning during manufacturing in order to introduce flavor – which limits versatility and leaves their products with the same after taste – Lika®’s proprietary food technology allows preparers to cook it as they would meat.

Lika® possesses the identical versatility people have come to expect from meat, including the ability to texture it from jerky to stew utilizing the same diverse cooking methods chefs use for animal protein. As a result, Lika® foods can be prepared as barbecued, fried, roasted, based, smoked or sautéed as LIka® products absorb flavor even better than animal protein, including sauces marinades and spices – all without any after taste.

From the California company’s meatballs, BBQ slices, breakfast patties and strips to its meatloaf, Buffalo wing nuggets and Southern Fried Chicken Nuggets, Lika® Heat & Serve foods offer enhanced protein adhesion that allows for any shapes or formats – just like their meat counterparts. At the same time, the texture of Lika® prepared cuisine is meaty yet tender, delicious with no harsh after-taste and completely satisfying without harming one’s health – or the health of the planet. For the weight-conscious, Lika® foods offer drastically reduced calories, saturated fats and cholesterol over their meat counterparts. And for the planet, each pound of Lika® product saves 1,800 gallons of water.

Amazing Protein Company CEO Swami Nathan combines a passion for cooking as a professional chef with an equal passion for building businesses within emerging categories. His distinguished career includes chef stints with vegetarian restaurants in New York City as well as senior executive positions with high-profile home entertainment companies. In launching The Amazing Protein Company, Swami set out to create his own line of quality vegan food expressly for his own family and friends. Swami experimented with several meat-alternatives but could never find one that was versatile enough to absorb different flavors in various meals that were staples in his home – curries, stews, stir-fries, BBQ and burgers. As a result, he set out to create a quality vegan product that would be as versatile as meat. After years of painstaking R&D – and an incredibly high bar Swami set for himself and his product – the recipe was perfected and Lika® was finally born.

“Lika® takes plant-based meat alternatives to an entirely new level,” said Swami Nathan, CEO of The Amazing Protein Company. The incredible taste, the natural texture and the unique ability to flavor every food item according to each chef’s vision and taste is what made Whole Foods Market instantly take notice – and take in the Lika® line of prepared vegan foods. We are excited to team with Whole Foods Market in introducing an extraordinary line of Heat & Serve foods within the ever-growing category of meat alternatives, and look forward to everyone sampling Lika® cuisine.”

CONTACT:

SSA Public Relations
David Syatt
david@ssapr.com
(818) 222-4000

SOURCE: SSA Public Relations

ReleaseID: 491281

SAN DIEGO, CA / ACCESSWIRE / February 28, 2018 / Go-Staff announced recently that it was a recipient of the Best of Staffing Award from Inavero. A national annual competition is held for this award, and results are collated from surveys taken by job candidates and clients of staffing companies. Cofounders Stacey Crumrine, CEO, and Scott Crumrine, CFO, are proud to receive this award, which is awarded to only about 2% of North American staffing companies, for service excellence because it represents the opinion of the people who matter – those who have benefited from the company’s services.

To be successful in the staffing industry, it takes hard work and getting some key factors right. Stacey Crumrine details how the following factors have led to the company’s success.

The Management and Staff

This family-owned firm has been operating since 2001 and has built up a strong management team. Stacey Crumrine believes that everyone who works at Go-Staff understands they are making a significant impact in the life of someone else and this is what drives their staff and is a reason for their success. The company culture is one of mutual respect, honesty, integrity, and professionalism. The team has many years of experience in the human resources field.

The Way Job Candidates Are Treated

The team at Go-Staff has a personalized approach to job candidates that takes far more into account than first impressions and what appears on a resume. They believe that a person’s character has as much bearing on suitability for a position as skills.

They look for qualities like integrity, perseverance, and competence. Carefully developed screening tests help recruiters to identify critical skills and abilities. Go-Staff has the reputation of being able to match job candidates and clients successfully, fulfilling its motto of ”The right staff right now.”

The Relationship with Clients

The Go-Staff personalized approach extends to its clients. It assigns an Account Manager to each client, so the client has one person to relate to and rely on. It goes far beyond simply sending candidates to work. The relationship of Go-Staff with clients is that of a strategic partner, helping them to source the right people and keep them. It entails understanding their requirements, whether it’s for long term, temp-to-hire positions, temporary workers or payroll. Also, regardless if someone is working temporarily for a client, they are employees of Go-Staff and enjoy the benefits of that. They might rotate between different clients but they are still considered full time employees of Go-Staff and are treated as part of the Go-Staff family. Placing and retaining the right staff improves the company’s labor costs and productivity.

Go-Staff’s relationship-focused approach builds stronger customer relations by paying heed to the client’s requirements and fulfilling commitments. They can customize solutions for clients whether this means finding 100 temporary workers for a week or a highly skilled professional for a permanent executive position. Their attitude is that if a client presents them with a challenge, they can meet it.

Follow Processes

Whether it is application or onboarding, processes are followed so that everyone in the company is on the same page. The company has offices in various cities in Southern California and what one branch does mirrors another. This speaks to its competency, consistency and professionalism.

A Benefit to Local Communities

Go-Staff appreciates the fact that it can contribute to local communities by helping people find jobs and support their families. It also works with community organizations that offer job programs for at-risk individuals, offering them a second chance. Partnering with private organizations to offer training opportunities to job seekers is another aspect of their community involvement.

Promote and Practice Core Values

From the top down, Go-Staff has a culture of integrity, professionalism, and excellent service that spreads through all levels of the organization. It believes in doing the right thing, no matter what, and gaining the award shows that people take notice of this and come back to them repeatedly.

Contact

Stacey Crumrine, CEO
Go-Staff, Inc.
info@go-staff.com
(858) 292-8562

SOURCE: Go-Staff

ReleaseID: 491274

SYDNEY, AUSTRALIA / ACCESSWIRE / February 28, 2018 / Parnell Pharmaceuticals Holdings Ltd. (OTC PINK: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the results of the resolution presented at its General Meeting of Shareholders held 22nd February 2018 (Australian Eastern Standard Time).

Submission of Matters to a Vote of Shareholders

On February 22, 2018 (AEST), the Company held a General Meeting of Shareholders (GM). The resolution subject to a vote at the GM was described in detail in the Company’s Notice of General Meeting and Explanatory Memorandum dated January 11, 2018.

The purpose of the meeting was for shareholders to consider and vote on a resolution for the removal of Dr. Alan Bell, Executive Chairman, as a director of the Company. This meeting was called by the Board of Directors, upon receipt of a notice from Robert Thomas Joseph, former Chief Executive and Director of the Company. The Directors (with Alan Bell abstaining) unanimously recommended that Shareholders vote against the resolution.

The total number of shares voted by shareholders on the resolution was 9,694,898 shares, which equated to 53.78% of the total number of shares outstanding. As such a majority of shareholders constituted a quorum for the GM.

The proxy count on the resolution was reported to the meeting as follows:

For

Against

Abstain

1,971,367

7,709,426

14,105

20.33%

79.52%

0.15%

The Chairman declared that a vote would be taken and declared the resolution lost by a count of proxy votes.

There being no further business, the Chairman declared the meeting closed.

Parnell Pharmaceuticals Holdings Ltd. logo

SOURCE: Parnell Pharmaceuticals Holdings Ltd

ReleaseID: 491270

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN) and certain of its officers. The class action, filed in United States District Court, for the District Southern District of California, and Docketed under 18-cv-00407, is on behalf of a class consisting of investors who purchased or otherwise acquired acquired Obalon securities: (i) pursuant and/or traceable to Obalon’s false and misleading Registration Statement and Prospectus, issued in connection with the Company’s initial public offering on or about October 5, 2016 (the “IPO” or the “Offering”); and/or (ii) on the open market between October 5, 2016 and January 23, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the Securities Act of 1933 (the “Securities Act”) and the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Obalon securities between October 5, 2016, and January 23, 2018, both dates inclusive, you have until April 16, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Obalon Therapeutics, Inc. is a medical device company that focuses on developing and commercializing medical gastric balloons for weight loss therapy. The Company claims that its initial product offering is the Obalon balloon system, a U.S. Food and Drug Administration (“FDA”) approved swallowable, gas-filled intra-gastric balloon designed to provide progressive and sustained weight loss in obese patients.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company recognized revenue in violation of Generally Accepted Accounting Principles (“GAAP”); (ii) the Company lacked adequate internal controls over accounting and financial reporting; and (iii) as a result, Obalon’s public statements were materially false and misleading at all relevant times.

On January 23, 2018, Obalon issued a press release entitled “Obalon Announces Termination of Public Offering of Common Stock,” revealing that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017.” The press release further stated that “Obalon’s Audit Committee will oversee an internal investigation of these allegations.”

On this news, Obalon’s share price fell $1.73, or 33.33%, to close at $3.46 on January 23, 2018, on unusually heavy volume. The $3.46 closing price represented a total decline of $11.54, or nearly 77%, from the IPO price of $15.00 per share.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

SOURCE: Pomerantz LLP

ReleaseID: 491256

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against LJM Funds Management, Ltd. (”LJM Partners” or the ”Company”) (NASDAQ: LJMIX) and certain of its officers. The class action, filed in United States District Court, for the Northern District of Illinois, Eastern Division, and docketed under 18-cv-01312, is on behalf of a class consisting of investors who purchased or otherwise acquired shares of the LJM Preservation and Growth Fund (”LJMIX” or the ”Fund”) between February 28, 2015 and February 7, 2018, both dates inclusive (the ”Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under the Securities Act of 1933 (the ”Securities Act”).

If you are a shareholder who purchased or otherwise acquired shares of the LJM Preservation and Growth Fund (”LJMIX” or the ”Fund”) between February 28, 2015 and February 7, 2018, both dates inclusive, you have until April 10, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

LJM Partners operates as an investment management firm. The Company specializes in volatility strategies aims to deliver low correlation to equity markets. LJM Funds Management conducts its business in the United States.

LJM Preservation & Growth Fund is an open-end fund incorporated in the United States. The Fund’s objective is capital appreciation. The Fund invests primarily in long and short call and put options on Standard & Poor’s 500 Index futures contracts and cash and cash equivalents, including high-quality short-term debt securities such as U.S. Treasury securities.

LJM Partners is headquartered in Chicago, Illinois and LJMIX shares trade on the NASDAQ under the ticker symbol ”LJMIX.”

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) LJMIX was not focused on capital preservation and left investors exposed to an unacceptably high risk of catastrophic losses; (ii) LJMIX had not taken appropriate steps to preserve capital in down markets and left investors exposed to an unacceptably high risk of catastrophic losses; and (iii) as a result of the foregoing, LJMIX shares traded at artificially inflated prices, and class members suffered significant losses and damages.

The truth began to emerge on February 5, 2018, when the S&P fell approximately 4.6%. In the wake of this drop, LJMIX plunged from $9.82 on February 2, to $1.94 on February 7, 2018, a loss of approximately 80%.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 491251

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 18-cv-01611, is on behalf of a class consisting of investors who purchased or otherwise acquired common shares of Bristol-Myers between January 27, 2015 and October 9, 2016, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Bristol-Myers securities between January 27, 2015, and October 9, 2016, both dates inclusive, you have until April 10, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here to join this class action]

Bristol-Myers is a global biopharmaceutical company that develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.

As of January of 2015, the Company’s CheckMate-026 study investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer (“NSCLC”) was underway.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Bristol-Myers’ CheckMate-026 trial was more likely to fail than Defendants were representing; (ii) Bristol-Myers’ CheckMate-026 trial failed more severely than the Company indicated in its August 5, 2016, announcements and disclosures concerning the trial; and (iii) as a result, Bristol-Myers’s public statements were materially false and misleading at all relevant times.

On August 5, 2016, the Company announced that its CheckMate-026 trial investigating the use of Opdivo (nivolumab) as monotherapy had failed because it did not meet its primary endpoint of progression-free survival.

On this news, the Company’s stock price fell $12.04 per share, or 16%, to close at $63.28 per share on August 5, 2016, on unusually heavy trading volume. The stock price continued to fall on the next trading day, declining another $2.98 per share, or 4.7%, on unusually heavy trading volume, to close at $60.30 per share on August 8, 2016.

Even after the announcement of August 5, 2016, Bristol-Myers continued to mislead the market before releasing the complete results of the trial, claiming that the release of all of the trial data would demonstrate the efficacy of Opdivo.

Then, on October 9, 2016, Bristol-Myers disclosed the final primary analysis of CheckMate-026, including the finding that overall survival was only 14.4 months for Opdivo versus 13.2 months for chemotherapy.

On this news, the Company’s stock price fell $5.62 per share, or 10.1%, to close at $49.81 per share on October 10, 2016, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 491249

LOS ANGELES, CA / ACCESSWIRE / February 28, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ekso Bionics Holdings, Inc. (“Ekso” or the “Company”) (NASDAQ: EKSO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between March 15, 2017, through December 27, 2017, inclusive (the “Class Period”), are encouraged to contact the firm before March 5, 2018, the lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, the Company failed to disclose that: (1) there was a material weakness in Ekso’s internal control over financial reporting and Ekso’s disclosure controls and procedures were not effective; and (2) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
Sherin Mahdavian, Esq.
The Schall Law Firm

SOURCE: The Schall Law Firm

ReleaseID: 491265

SAN DIEGO, CA / ACCESSWIRE / February 28, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of NYSE: ALL shares against Allstate Corp over alleged violations of Securities Laws.

Investors, who purchased shares of Allstate Corp (NYSE: ALL) in October 2014 or earlier and continue to hold any of those NYSE: ALL shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On November 10, 2016, a lawsuit was filed against Allstate Corp over alleged securities laws violations. The plaintiff alleged that the issued allegedly false and misleading statements and/or failed to disclose adverse information regarding the Company’s business and prospects, including that the reason for the sudden spike in its auto claims frequency, which defendants claimed was due to external events beyond the Company’s control, including the weather and increased miles driven, was actually the result of Allstate’s growth in its auto policy business through higher risk drivers, and that as a result of defendants’ allegedly false statements and/or omissions, Allstate Corp stock traded at artificially inflated prices between October 30, 2014 and August 3, 2015, reaching a high of $72.58 per share, and certain of the Company’s insiders, including its CEO, were able to sell their Allstate shares at artificially inflated prices.

On March 30, 2017, an amended complaint was filed and on June 1, 2017, the defendants filed their motion to dismiss the case. On February 27, 2018, the judge denied the motion to dismiss the lawsuit.

Those who purchased Allstate Corp (NYSE: ALL) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 491231

STROUDSBURG, PA / ACCESSWIRE / February 28, 2018 / ESSA Bancorp, Inc. (NASDAQ: ESSA), the holding company for ESSA Bank & Trust, a $1.8 billion asset institution providing full service retail and commercial banking, financial and investment services, today announced that its Board of Directors declared a dividend of nine cents ($0.09) per share. The dividend is payable to shareholders of record as of March 16, 2018, payable on March 30, 2018.

This will be the fortieth consecutive quarter ESSA Bancorp, Inc. has paid a dividend to its shareholders. ESSA became a public company in April 2007.

About the Company

ESSA Bank & Trust, a wholly-owned subsidiary of ESSA Bancorp, Inc., has total assets of $1.8 billion and is the leading service-oriented financial institution headquartered in Stroudsburg, Pennsylvania. The Bank maintains its corporate headquarters in downtown Stroudsburg, Pennsylvania and has 26 community offices throughout the Greater Pocono, Lehigh Valley, Scranton/Wilkes-Barre and western Philadelphia markets in Pennsylvania. In addition to being one of the region’s largest mortgage lenders, ESSA Bank & Trust offers a full range of retail, commercial financial services, and financial advisory and asset management capabilities. ESSA Bancorp, Inc. stock trades on the NASDAQ Global MarketSM under the symbol ”ESSA.” ESSA Bancorp, Inc. became a public company in April, 2007.

Forward-Looking Statements

Certain statements contained herein are ”forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements may be identified by reference to a future period or periods, or by the use of forward-looking terminology, such as ”may,” ”will,” ”believe,” ”expect,” ”estimate,” ”anticipate,” ”continue,” or similar terms or variations on those terms, or the negative of those terms. Forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, those related to the economic environment, particularly in the market areas in which the Company operates, competitive products and pricing, fiscal and monetary policies of the U.S. Government, changes in government regulations affecting financial institutions, including compliance costs and capital requirements, changes in prevailing interest rates, acquisitions and the integration of acquired businesses, credit risk management, asset-liability management, the financial and securities markets and the availability of and costs associated with sources of liquidity.

The Company wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company wishes to advise readers that the factors listed above could affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake and specifically declines any obligation to publicly release the result of any revisions, thatmay be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contact:

Gary S. Olson, President & CEO
Corporate Office: 200 Palmer Street
Stroudsburg, Pennsylvania 18360
Telephone: (570) 421-0531

SOURCE: ESSA Bancorp, Inc.

ReleaseID: 491225